Insider trading

Period: 120 months Stock: MRK Minimum amount: $1M × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

103 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

103 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

103 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

103 decisions over 120 months Remove this filter
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
103 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
103 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

103 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
13 Aug 2026
Guindo Chirfi EVP, Access, Policy & Comms
Sold at will
$1.35M 10,000 at 135.00
21.5%
Not planned
12 Aug 2026
Zachary Jennifer EVP, General Counsel
Sold at will
$10.72M 80,315 at 133.46
63.8%
Sold half or more
12 Aug 2026
DeLuca Richard R. EVP&Pres, Merck Animal Heallth
Sold at will 2×
$1.54M 11,699 at 131.63
9.6%
Not planned
11 Aug 2026
DeLuca Richard R. EVP&Pres, Merck Animal Heallth
Sold at will 2×
$1.69M 12,837 at 131.76
9.5%
Not planned
10 Aug 2026
DeLuca Richard R. EVP&Pres, Merck Animal Heallth
Sold at will
$2.71M 20,784 at 130.43
13.4%
Not planned
6 Aug 2026
Guindo Chirfi EVP, Access, Policy & Comms
Sold at will
$1.97M 15,000 at 131.00
24.3%
Not planned
5 Aug 2026
Williams David Michael EVP,Chief Info&Digital Officer
Sold at will 3×
$6.81M 52,847 at 128.77
62.5%
Sold half or more
5 Aug 2026
Maraldo David R. EVP & Pres. MMD
Sold at will 3×
$2.41M 18,706 at 128.72
50.7%
Sold half or more
12 Feb 2026
Guindo Chirfi Chief Marketing Officer
Sold at will
$1.21M 10,000 at 121.46
14.2%
Not planned
10 Feb 2026
Li Dean Y Executive VP & President, MRL
Sold at will
$1.20M 10,235 at 117.52
10.0%
Not planned
9 Feb 2026
Zachary Jennifer EVP, General Counsel
Sold at will 3×
$14.49M 121,573 at 119.15
63.8%
Sold half or more
9 Feb 2026
Guindo Chirfi Chief Marketing Officer
Sold at will
$1.18M 10,000 at 118.41
12.4%
Not planned
6 Feb 2026
DeLuca Richard R. EVP&Pres, Merck Animal Heallth
Sold at will
$4.56M 37,685 at 120.92
19.0%
Not planned
6 Feb 2026
Oosthuizen Johannes Jacobus President, U.S. Market
Sold at will
$1.83M 15,000 at 121.87
41.4%
Not planned
5 Feb 2026
Guindo Chirfi Chief Marketing Officer
Sold at will
$2.44M 20,000 at 121.88
19.9%
Not planned
4 Feb 2026
Davis Robert M Chairman, CEO & President
Sold at will 2×
$5.60M 47,434 at 118.04
9.7%
Not planned
4 Feb 2026
Sold at will
$5.02M 41,997 at 119.61
31.8%
Not planned
4 Feb 2026
Li Dean Y Executive VP & President, MRL
Sold at will
$1.79M 15,087 at 118.77
12.9%
Not planned
5 Feb 2025
Bought
$1.33M 15,000 at 88.50
×15
First buy on file
14 Feb 2024
Davis Robert M Chairman, CEO & President
Sold at will
$10.66M 85,021 at 125.40
19.6%
Not planned
14 Feb 2024
Sold at will
$4.81M 38,291 at 125.50
42.9%
Not planned
13 Feb 2024
Davis Robert M Chairman, CEO & President
Sold at will 2×
$18.88M 150,000 at 125.85
30.1%
Not planned
9 Feb 2024
Li Dean Y Executive VP & President, MRL
Sold at will
$1.85M 14,702 at 125.50
24.1%
Not planned
2 Feb 2024
MIZELL STEVEN EVP, Chief HR Officer
Sold at will
$6.42M 50,694 at 126.65
68.2%
Sold half or more
2 Feb 2024
Zachary Jennifer EVP, General Counsel
Sold at will
$6.28M 49,499 at 126.97
63.0%
Sold half or more
2 Feb 2024
Oosthuizen Johannes Jacobus President, U.S. Market
Sold at will
$2.41M 18,959 at 127.18
44.8%
Not planned
8 Nov 2023
DeLuca Richard R. EVP&Pres, Merck Animal Heallth
Sold at will
$4.60M 43,823 at 105.03
28.2%
Not planned
4 May 2023
Zachary Jennifer EVP, General Counsel
Sold at will
$2.25M 19,141 at 117.59
35.3%
Not planned
4 May 2023
Karachun Rita A Sr. VP Fince-Global Controller
Sold at will
$1.87M 15,875 at 117.53
25.8%
Not planned
3 May 2023
MIZELL STEVEN EVP, Chief HR Officer
Sold on a plan 4×
$6.36M 53,400 at 119.01
62.8%
Sold half or more
1 May 2023
DeLuca Richard R. EVP&Pres, Merck Animal Heallth
Sold at will
$8.75M 75,436 at 116.03
32.8%
Not planned
28 Apr 2023
Davis Robert M Chairman, CEO & President
Sold at will
$16.47M 143,329 at 114.93
34.5%
Not planned
28 Apr 2023
DeLuca Richard R. EVP&Pres, Merck Animal Heallth
Sold at will
$7.61M 66,163 at 115.00
30.0%
Not planned
13 Apr 2023
Chattopadhyay Sanat Exe V-P & Pres. MMD
Sold at will 2×
$15.43M 134,055 at 115.07
100%
Sold half or more
3 Feb 2023
Zachary Jennifer EVP, General Counsel
Sold, plan not stated
$7.78M 75,436 at 103.17
58.3%
Sold half or more
9 Jan 2023
Chattopadhyay Sanat Exe V-P & Pres. MMD
Sold, plan not stated 5×
$9.43M 83,994 at 112.29
74.0%
Sold half or more
10 Nov 2022
MIZELL STEVEN EVP, Chief HR Officer
Sold, plan not stated
$1.52M 15,000 at 101.42
31.8%
9 Nov 2022
Davis Robert M CEO & President
Sold, plan not stated 3×
$17.17M 167,613 at 102.44
40.4%
8 Nov 2022
MIZELL STEVEN EVP, Chief HR Officer
Sold, plan not stated
$2.02M 20,000 at 101.00
38.4%
7 Nov 2022
FRAZIER KENNETH C Executive Chair
Sold, plan not stated 3×
$23.47M 235,769 at 99.55
25.2%
7 Nov 2022
Oosthuizen Johannes Jacobus President, U.S. Market
Sold, plan not stated
$4.53M 45,561 at 99.47
71.1%
Sold half or more
4 Nov 2022
FRAZIER KENNETH C Executive Chair
Sold, plan not stated 2×
$23.17M 235,000 at 98.61
25.1%
3 Nov 2022
FRAZIER KENNETH C Executive Chair
Sold, plan not stated 2×
$23.20M 235,000 at 98.71
25.1%
2 Nov 2022
FRAZIER KENNETH C Executive Chair
Sold, plan not stated 2×
$29.97M 300,000 at 99.91
30.0%
1 Nov 2022
FRAZIER KENNETH C Executive Chair
Sold, plan not stated 3×
$29.94M 300,000 at 99.81
29.8%
31 Oct 2022
FRAZIER KENNETH C Executive Chair
Sold, plan not stated 2×
$30.22M 300,000 at 100.75
29.8%
28 Oct 2022
FRAZIER KENNETH C Executive Chair
Sold, plan not stated 3×
$56.87M 567,084 at 100.28
44.5%
28 Oct 2022
DeLuca Richard R. EVP&Pres, Merck Animal Heallth
Sold, plan not stated
$16.50M 164,557 at 100.26
54.6%
Sold half or more
28 Oct 2022
Zachary Jennifer EVP, General Counsel
Sold, plan not stated 2×
$16.42M 165,255 at 99.38
81.3%
Sold half or more
28 Oct 2022
Chattopadhyay Sanat Exe V-P & Pres. MMD
Sold, plan not stated
$10.04M 100,292 at 100.10
68.7%
Sold half or more
Showing 1–50 of 103. Page 1 of 3 Older →